Research links repeated use of Depo-Provera (the medroxyprogesterone birth-control injection) to meningioma brain tumors. Cases against Pfizer are consolidated as MDL 3140, and a settlement in principle was reached in 2026. We never sell your information.
A large 2024 study associated long-term use of the injectable contraceptive medroxyprogesterone (Depo-Provera) with a markedly higher risk of intracranial meningioma. In December 2025 the FDA added a meningioma warning to the label. The federal cases are consolidated as MDL 3140 before Judge Casey Rodgers in the Northern District of Florida, and in June 2026 Pfizer and plaintiffs' leadership reached a settlement in principle.
The signal is recent and strong. A 2024 study of contraceptive use found that prolonged use of medroxyprogesterone acetate, the active ingredient in Depo-Provera, was associated with a substantially higher risk of developing an intracranial meningioma, a tumor of the membranes around the brain.
In December 2025 the FDA added a meningioma warning to the Depo-Provera label. The federal cases are consolidated as MDL 3140 before Judge Casey Rodgers in the Northern District of Florida. A June 2026 settlement in principle covers eligible plaintiffs already in the federal MDL; it does not resolve every case, and state-court options may remain.
The documented basis for these claims:
Meningioma is the core diagnosis; other brain-tumor diagnoses may be evaluated individually.
A tumor arising from the membranes surrounding the brain and spinal cord. Often requires surgery or radiation and long-term monitoring.
Link to Depo-Provera use: The 2024 BMJ study specifically linked prolonged medroxyprogesterone use to meningioma.
Non-meningioma brain-tumor diagnoses are reviewed case by case; whether they fit the intake depends on the specific firm and facts.
Link to Depo-Provera use: The core scientific link is to meningioma specifically.
The 60-second check above tells you if your situation fits the criteria. Free, confidential, no obligation.
Four steps. After the first one, the attorney's team does almost everything.
Three questions confirm the basics: Depo-Provera use, diagnosis, and attorney status.
About 60 seconds.An attorney from the network reviews your answers and follows up to confirm your situation fits intake criteria.
1 to 2 business days.If accepted, the intake team collects your imaging, pathology, treatment, and injection history.
3 to 6 weeks.Once records are complete, your claim is filed. Your attorney handles it through resolution. You can withdraw before signing a representation agreement.
Filing within 30 days of records being complete.Every state sets a filing deadline. With a settlement in principle now in place for the federal MDL, claim windows can move quickly.
If you are unsure whether you are still within the window, run the check now. The attorney review is free and the deadline question is evaluated first.
claimscout is not a law firm. We connect you with attorneys from a vetted network of firms that handle Depo-Provera (MDL 3140) claims.
claimscout is a referral service. We do not provide legal advice and are not a substitute for an attorney-client relationship. Sponsored attorney advertising. Past results do not guarantee future outcomes.
You do not need to prove the medicine on Depo-Provera. A major study and an FDA label change already did. Your job is to confirm you received the shots and were diagnosed with a meningioma.
The Depo-Provera litigation is early, and we would rather be straight about that. claimscout is not a law firm. No case has gone to trial yet, and the 2026 settlement is in principle only, with per-person terms not publicly disclosed.
Public record: federal MDL-3140 docket and reported settlement status.
No verdicts or final settlement values exist yet in this litigation, and nothing here is a promise of compensation. Past results do not guarantee any future outcome. This is attorney advertising, not legal advice.
A 2024 study found that prolonged use of medroxyprogesterone acetate, the active ingredient in Depo-Provera, was associated with a significantly higher risk of intracranial meningioma. The FDA added a meningioma warning to the label in December 2025.
The June 2026 settlement in principle covers eligible cases already in the federal MDL and does not resolve every case; state-court options may remain. Whether you can still file depends on your situation, which the attorney review evaluates.
The scientific link is strongest with prolonged use, generally a year or more. The eligibility check and attorney review sort out whether your history fits.
Meningioma is the core diagnosis. Other brain-tumor diagnoses are reviewed case by case.
Usually not disqualifying. Pharmacy and clinic records can often be retrieved, and a sworn declaration about your injection history helps. The intake team assists with records.
We connect you. The check routes qualified cases to a Depo-Provera-experienced attorney, and you can accept or decline.
Nothing. We get paid by the law firms or affiliate fees from the court-appointed administrator. You pay zero up front and zero out of any payout you receive.
Only if you check the consent box. We give you the choice. If you do not consent, your claim is captured and we route it to the administrator directly without sharing your phone number.
Yes, always. If we route your claim to a law firm, you can choose to file directly with the same firm or pick a different one. We exist because most people throw the notice letter away. We make it not happen.
No. We are not a law firm and do not provide legal advice. We are a platform that captures your claim, qualifies it, and routes it to the court-appointed administrator or a law firm of your choice.